Advertisement

Banxia Xiexin Decoction (半夏泻心汤) Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review

  • Li Su
  • Miao-miao Wang
  • Meng-ran Xu
  • Xiao Wang
  • Hong-zhen Xia
  • Mei Zhang
  • Lei Zheng
  • Yao-dong Zhu
  • Ming-qi Wang
  • Ping LiEmail author
Case Report
  • 25 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Supplementary material

11655_2019_3152_MOESM1_ESM.pdf (559 kb)
Banxia Xiexin Decoction (半夏 泻心汤) Combined with Afatinib in Treatment of Advanced Gallbladder Cancer: Case Report and Literature Review

References

  1. 1.
    Sharma A, Sharma KL, Gupta A, Yadav A, Kumar A. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: Recent update. World J Gastroenterol 2017;23:3978–3998.CrossRefGoogle Scholar
  2. 2.
    Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014;6:99–109.Google Scholar
  3. 3.
    Kim BJ, Hyung J, Yoo C, Kim KP, Park SJ, Lee SS, et al. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients. Cancer Chemother Pharmacol 2017;80:209–215.CrossRefGoogle Scholar
  4. 4.
    Neal JW, Sledge GW. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours. Nat Rev Clin Oncol 2014;11:627–638.CrossRefGoogle Scholar
  5. 5.
    Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ, He WF, et al. Fuzheng Kang'ai Decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial. Trials 2015;16:146–152.CrossRefGoogle Scholar
  6. 6.
    Ichiki M, Wataya H, Yamada K, Tsuruta N, Takeoka H, Okayama Y, et al. Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinibinduced diarrhea and skin rash in patients with non-small cell lung cancer. Onco Targets Ther 2017;10:5107–5113.CrossRefGoogle Scholar
  7. 7.
    Yamaguchi O, Kawashima A, Shiono A, Maeno Y, Ishikawa R, Masumoto A, et al. Hange-Shashin-to for preventing diarrhea during afatinib therapy. Cancer Chemother (Jpn) 2015;42:581–593.Google Scholar
  8. 8.
    Shen HX, Song HW, Xu XJ, et al. Clinical epidemiological survey of gallbladder carcinoma in northwestern China, 2009-2013: 2379 cases in 17 centers. Chronic Dis Transl Med 2017;3:60–66.CrossRefGoogle Scholar
  9. 9.
    Romiti A, D'Antonio C, Zullo A, Di Rocco R, Barucca V, Durante V, et al. Chemotherapy for the biliary tract cancers: moving toward improved survival time. J Gastrointest Cancer 2012;43:396–404.CrossRefGoogle Scholar
  10. 10.
    Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012;27:642–653.CrossRefGoogle Scholar
  11. 11.
    Nam AR, Kim JW, Cha Y, Ha H, Park JE, Bang JH, et al. Therapeutic implication of HER2 in advanced biliary tract cancer. Oncotarget 2016;7:58007–58021.Google Scholar
  12. 12.
    Park K, Kim KP, Park S, Chang HM. Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer. Asia Pac J Clin Oncol 2017;13:13–20.CrossRefGoogle Scholar
  13. 13.
    Law LY. Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. J Clin Oncol 2012;30:e271–e283.CrossRefGoogle Scholar
  14. 14.
    McNamara MG, Metran-Nascente C, Knox JJ. State-of-theart in the management of locally advanced and metastatic gallbladder cancer. Curr Opin Oncol 2013;25:425–431.CrossRefGoogle Scholar
  15. 15.
    Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway. Nat Genet 2014;46:872–886.CrossRefGoogle Scholar
  16. 16.
    Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 2012;343:342–350.CrossRefGoogle Scholar
  17. 17.
    Li L, Zhang L, Yang CC. Multi-target strategy and experimental studies of traditional Chinese medicine for Alzheimer's disease therapy. Curr Top Med Chem 2016;16:537–548.CrossRefGoogle Scholar
  18. 18.
    Lu H, Qin J, Han N, Xie F, Gong L, Li C. Banxia Xiexin Decoction is effective to prevent and control irinotecan-induced delayed diarrhea in recurrent small cell lung cancer. Integr Cancer Ther 19 2018:1534735418801532.Google Scholar
  19. 19.
    Kim HR, Lee GS, Kim MS, Ryu DG, So HS, Moon HC, et al. Effects of Banxia Xiexin Decoction on cisplatin-induced apoptosis of human A549 lung cancer cells. Chin J Integr Med 2018;24:436–441.CrossRefGoogle Scholar
  20. 20.
    Chen G, Yang Y, Liu M, Teng Z, Ye J, Xu Y, et al. Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol 2015;166:149–156.CrossRefGoogle Scholar
  21. 21.
    Xiao J, Zhang YF, Wang Y, An R, Wang XH. Study on effect of different compatibility of saponins contained in Banxia Xiexin Decoction on intestinal bacterium metabolism. China J Chin Mater Med (Chin) 2013;38:611–617.Google Scholar

Copyright information

© Chinese Association of the Integration of Traditional and Western Medicine 2019

Authors and Affiliations

  • Li Su
    • 1
  • Miao-miao Wang
    • 1
  • Meng-ran Xu
    • 1
  • Xiao Wang
    • 2
  • Hong-zhen Xia
    • 3
  • Mei Zhang
    • 1
  • Lei Zheng
    • 1
  • Yao-dong Zhu
    • 1
  • Ming-qi Wang
    • 1
  • Ping Li
    • 1
    Email author
  1. 1.Department of Integrative Medicine OncologyFirst Affiliated Hospital of Anhui Medical UniversityHefeiChina
  2. 2.Department of RadiologyFirst Affiliated Hospital of Anhui Medical UniversityHefeiChina
  3. 3.Department of PathologyAnhui Provincial HospitalHefeiChina

Personalised recommendations